Manufacturers use AI and design of experiments to optimize injection molding, cut costs, and speed time-to-market for complex ...

Q4 2025 Earnings Call March 24, 2026 4:30 PM EDTCompany ParticipantsMiranda Benvenuti - Investor Relations ExecutivePeter Altman ...

Good afternoon, and thank you for joining us for our fourth quarter 2025 earnings call and business update. Joining me today on this call are my colleagues, Dr. James Cassella, our Chief Development ...

Q4 2025 Management View Jennifer Good, CEO, reported that "2025 was a major inflection point for growth at Trevi, driven by our positive data readouts in both the CORAL trial in patients with ...

ELLICOTT CITY, MD, UNITED STATES, March 19, 2026 /EINPresswire.com/ — The Hereditary Neuropathy Foundation (HNF) will host ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the 45th subject has been enrolled in its pivotal Phase 2B/3 MIRACLE trial evaluating Annamycin in ...

Karan Arora, senior vice president of advanced assays, AI, and pharma services at Leica Biosystems outlines the critical role ...

Nicolás Cavero, the digital creator behind 'futurecarsnow', has CGI-cooked the 2027 BMW 7 Series (G70) LCI - Life Cycle ...

OverT builds scalable, cost-effective immune therapies for solid tumors using its data-driven discovery platformsNEW ...

Technically, the Classic 650 isn’t “all-new.” It was launched worldwide last year, but, for whatever reason, not in North ...

Trevi Therapeutics Inc (TRVI) outlines pivotal trial plans and robust cash position, while addressing potential challenges in ...

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the ...